Real-Life Use and Effectiveness of Adjuvant Trastuzumab in Early Breast Cancer Patients: A Study of the Southeast Netherlands Breast Cancer Consortium

Abstract

© AlphaMed Press. Background. The impact of drug prescriptions in real life as opposed to strict clinical trial prescription is only rarely assessed, although it iswell recognized that incorrect usemay harm patients and may have a significant impact on health care resources.We investigated the use and effectiveness of adjuvant trastuzumab in daily practice compared with the effectiveness in clinical trials. Methods.We included all patients with stage I–III invasive breast cancer, irrespective of human epidermal growth factor receptor 2 (HER2) status, diagnosed in five hospitals in the southeast of The Netherlands in 2005–2007. We aimed to assess the actual use of adjuvant trastuzumab in early HER2-positive breast and its efficacy in daily practice. Results. Of 2,684 patients included, 476 (17.7%) had a HER2-positive tumor. Of these, 251 (52.7%) patients had an indication for trastuzumab treatment of which 196 (78.1%) patients actually received it. Of the 225 patients without an indication, 34 (15.1%) received trastuzumab. Five-year disease-free survivalwas 80.7%for (n=5230) patients treated with versus 68.2% for (n=5 246) patients not treated with trastuzumab (p=5 .0023), and 5-year overall survival rates were 90.7% and 77.4%, respectively (p=5 .0002). The hazard ratio for disease recurrence was 0.63 (95% confidence interval, 0.37–1.06) for trastuzumab when adjusting for potential confounders. Conclusion. This study shows that in real life, patients treated with trastuzumab in early-stage HER2-positive breast cancer had a 5-year disease-free and overall survival comparable to prior randomized trials. For informative decision making, reallife data are of additional value, providing insight on outcome of patients considered ineligible for treatment.